• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, February 2, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

McMaster researchers identify how VITT happens

Bioengineer by Bioengineer
July 7, 2021
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The work will have both diagnostic and therapeutic implications

IMAGE

Credit: James Smith/McMaster University

Hamilton, ON (July 7, 2021) – A McMaster University team of researchers recently discovered how, exactly, the COVID-19 vaccines that use adenovirus vectors trigger a rare but sometimes fatal blood clotting reaction called vaccine-induced immune thrombotic thrombocytopenia or VITT.

The findings will put scientists on the path of finding a way to better diagnose and treat VITT, possibly prevent it and potentially make vaccines safer.

The researchers’ article was fast-tracked for publication today by the prestigious journal Nature in its accelerated article preview because of the importance of the research.

“Our work also answers important questions about the connection between antibodies and clotting,” said Ishac Nazy, principal investigator and corresponding author of the study. He added it will have both diagnostic and therapeutic implications.

Nazy is the scientific director of the McMaster Platelet Immunology Laboratory and an associate professor of medicine for the Michael G. DeGroote School of Medicine at McMaster.

The COVID-19 vaccines using adenoviral vectors, such as those from AstraZeneca and Johnson and Johnson, are associated with the VITT clotting disorder caused by unusual antibodies to blood platelets that are triggered by the vaccine.

The study shows, at a molecular level, how those unusual antibodies stick to components from blood platelets causing them to trigger clot formation.

“The antibodies stick to the platelet protein called platelet factor 4 (PF4) in a very unique and specific orientation, which allows them to align with other antibodies and platelets in the precise formation that leads to a self-perpetuating vicious cycle of clotting events,” said Nazy.

“These disease-causing aggregates quickly activate platelets, creating a highly intense clotting environment in patients,” he added.

The dangerous reaction to the adenovirus vector vaccines has been found to occur in one in 60,000 of people receiving the vaccine in Canada.

“The intention of our study was to better understand how the severe clots which characterize VITT develop,” said Donald Arnold, study co-investigator and co-medical director of the McMaster Platelet Immunology Laboratory.

“A basic principle of medical care is to understand how the disorder happens and, in doing so, develop better treatments.”

John Kelton, co-investigator of the study and co-medical director of the McMaster Platelet Immunology Laboratory, added: “We believe that this study is important because it clarifies how the clotting ensues, and because we have been able to identify the molecules involved.

“The next step is to develop a rapid diagnostic and accurate test to diagnose VITT. Our major interest is now to move upstream from how the clots happen to preventing them from occurring.”

Current rapid tests yield false-negative results, and testing relies on more time-consuming tests to confirm VITT. This study now explains why the rapid tests frequently fail and allows for new strategies to improve diagnostic testing.

The investigators altered the molecular composition of the PF4 protein and, using this technology, were able to identify the binding region on the protein.

###

The research team included Angela Huynh, a research scientist in the McMaster Platelet Immunology Laboratory, and Mercy Daka, a graduate student of McMaster’s Department of Biochemistry and Biomedical Sciences.

The researchers thanked the agencies supporting the research, including the Public Health Agency of Canada, the Canadian Institutes of Health Research (CIHR), and the Ontario Ministry of Health.

Editors:

A link to the paper may be found here: https://fhs.mcmaster.ca/plateletimmunology/updates.html

An illustration of VITT, a picture of the authors and b-roll in the platelet lab are available for downloading at https://macdrive.mcmaster.ca/d/d7054b21b11a4829b4db/

For information, please contact:

Veronica McGuire

Media Relations

Faculty of Health Sciences

McMaster University

289-776-6952

[email protected]

Media Contact
Veronica McGuire
[email protected]

Tags: HematologyMedicine/HealthVaccines
Share14Tweet9Share2ShareShareShare2

Related Posts

Untreated control sample

Nematodes can help us detect indoor air impurities

February 2, 2023
Genes responsible for coronary artery disease, world’s No. 1 killer, identified

Genes responsible for coronary artery disease, world’s No. 1 killer, identified

February 2, 2023

Tuberculosis vaccine does not protect elderly against COVID-19

February 2, 2023

Urinary tract infections impair the sex life, sleep and exercise of over half of women who experience them, and are associated with reduced quality of life, in U.S. survey

February 1, 2023
Please login to join discussion

POPULAR NEWS

  • Jean du Terrail, Senior Machine Learning Scientist at Owkin

    Nature Medicine publishes breakthrough Owkin research on the first ever use of federated learning to train deep learning models on multiple hospitals’ histopathology data

    65 shares
    Share 26 Tweet 16
  • First made-in-Singapore antibody-drug conjugate (ADC) approved to enter clinical trials

    58 shares
    Share 23 Tweet 15
  • Metal-free batteries raise hope for more sustainable and economical grids

    41 shares
    Share 16 Tweet 10
  • One-pot reaction creates versatile building block for bioactive molecules

    37 shares
    Share 15 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Near-zero-dispersion soliton and broadband modulational instability Kerr microcombs in anomalous dispersion

Astronomers observe light bending around an isolated white dwarf

Nematodes can help us detect indoor air impurities

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 42 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In